Symetis' second-gen TAVI device shows positive trial results

04/5/2013 | MassDevice.com (Boston)

Symetis' Acurate TA device, a second-generation transcatheter aortic valve implant already approved in Europe, showed a 98% rate of procedural success and minimal valve leakage in a 250-patient clinical study. The device also showed a 6.8% all-cause mortality rate at 30 days, which the company said was one of the lowest rates reported for TAVI devices.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN